Celltrion Pharmaceutical announced on the 25th that it recorded 233.5 billion won in sales and 23.6 billion won in operating profit last year. This is an increase of 34% and 60% compared to the same period last year, respectively.
Net income was 20.9 billion won, an increase of 143% from the previous year.
Annual sales, operating profit, and net profit all recorded the highest levels since the incorporation of Celltrion Group in 2009.
Celltrion Pharm cited the growth of all business divisions, including chemicals and biopharmaceuticals, as the driving force behind strong earnings. In particular, sales of global chemical products, which have expanded in earnest from the third quarter of last year, have been effective.
Celltrion Pharmaceutical’s flagship product, Godex, a soy sauce solution, recorded sales of 65.7 billion won, the largest single item. The sales of three antibody biosimilars, Remsima, Hezuma, and Truxima, also recorded 43.3 billion won, a growth of about 14% year-on-year. In addition, 6 kinds of global chemical drugs, including CT-G7, a human immunodeficiency virus (HIV) treatment, increased production and shipments, achieving sales of 43 billion won.
This year’s Celltrion Pharmaceuticals has secured sales rights at the end of last year, including’Edalbi’,’Nesina’,’Actos’,’Fightoven’, and’Albochill’. ) We plan to strengthen our market penetration.
In addition, the company plans to devote all efforts to successfully settle the market for’Remsima SC’, a subcutaneous injection-type autoimmune disease treatment recently launched in Korea.
Related Articles
Celltrion enters European product approval review for’corona treatment’
Celltrion catches’Corona South African mutation’
Seo Jeong-jin Celltrion “Can enter the vaccine business for technology sovereignty”
Celltrion’Corona treatment’ started to supply free of charge to medical institutions
It also speeds up the preparation of the PFS line for production of subcutaneous injection formulations. The PFS production line at the Cheongju plant, which was completed at the end of last year, is capable of producing 18 million SC formulations, and plans to start production once GMP approval by global regulatory agencies such as the European Medicines Agency (EMA) is completed.
An official from Celltrion Pharmaceutical said, “Last year, we were able to accelerate our growth by improving production efficiency and expanding commercial production items, making achievements in the areas we prepared for a long time. This year, as we have secured a number of promising products such as’Remsima SC’ as well as new diabetes treatments and hypertension treatments, we expect to continue high growth based on product competitiveness.” He added, “We will do our best to continue steadily growing in various areas other than the liver disease treatment area, which was traditionally strong.”